2.1. Patients
cancer of different origin (, weight loss
END-STAGE KIDNEY DISEASE
This study was approved by the Ethics Committee of the Reina Sofia University Hospital (Cordoba, Spain; reference number 4788), which was conducted in accordance with the Declaration of Helsinki and according to national and international guidelines. This is a prospective open-label study, wherein a written informed consent form was signed by every individual before inclusion into the study. All patients received information before the inclusion and were only included if they agreed to participate. The inclusion criteria were the following: patients whose sex is male or female, aged > 18 years, with cancer of different origin treated with systemic treatment (chemotherapy, radiotherapy or combination treatment) that presented with weight loss > 5% during the previous three months or >10% during the previous six months. Exclusion criteria were the following: end-stage kidney disease and life expectancy < 2 weeks. Sample size was calculated based on the usual number of treated patients during 6 months in this hospital. Forty-six consecutive patients with cancer of different origin (